A pharmaco-epidemiological study of psoriasis (original) (raw)
Related papers
Survey and Comparative Study on Treatment of Psoriasis
International Journal of Pharmaceutical Sciences Review and Research
Psoriasis is autoimmune chronic inflammatory disease which has affected 2% of total population but varies according to region. The main purpose of this work to conduct survey and comparatively study of various antipsoriatic drugs for their therapeutic dose , potency & their side effects . so that it will help in correct choice of medication to treat it. Different classes of drugs have been compared such as biologic & non biologic etc. Now a days combination therapy is also used which is also compared in this article. A survey-based study was conducted amongst the patients, pharmacists, & physicians in March 2021. A questionnaire was prepared. For the patient survey we had focused on various parameters and prepared a questionary. Later we had taken the print out and we asked that questions to patient, pharmacists and physicians. Our main aim for conducting the survey was to segment the patient on the basis of their age, gender, also treatment they have been taking. From this survey w...
International Journal of Research in Medical Sciences
Background: Psoriasis is a chronic skin disorder that can have different clinical presentations. Topical corticosteroids are the primary therapy for psoriasis, but there are many new drug options approved for its treatment. The aim of this study was to assess the prescription patterns and disease distribution of psoriasis patients in a tertiary care center in central India. Methods: We conducted a retrospective observational study of 195 psoriasis patients treated in the Dermatology OPD of a teaching hospital from September 2020 to June 2021. We analyzed patient data for demographics, disease characteristics, and medications prescribed using frequency distributions in Microsoft Excel. Results: Plaque psoriasis was the most common clinical variant among the patients, and the male to female ratio was 1.5:1. February had the highest number of patients treated, indicating an aggravation of symptoms during cold weather. Most patients (93.33%) were prescribed topical corticosteroids, with...
The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review
Journal of the European Academy of Dermatology and Venereology, 2006
Conventional systemic therapies and phototherapy for psoriasis are limited by safety concerns that may preclude long-term treatment with these agents. To estimate the unmet need for safe and effective treatments for psoriasis. A survey was conducted at three psoriasis outpatient clinics in Europe. Male and female patients of any age with psoriasis requiring more than topical treatment were eligible to participate in the survey. Patient data were obtained from patients' answers to a questionnaire as well as by a chart review of each participating patient. The survey questionnaire addressed various aspects of psoriasis, including demographics and disease characteristics, treatment history, pre-existing medical conditions, and patient satisfaction with treatments received. A total of 301 patients participated in the survey, with approximately 100 patients from each centre. Nearly 90% of patients had received at least one systemic therapy or phototherapy for psoriasis, with 39% of patients receiving three or more. Ultraviolet B (UVB), methotrexate, psoralen plus ultraviolet A (PUVA), retinoids and cyclosporin were the most commonly used agents. Inadequate response, reported by patients as no change or worsening of disease with treatment, ranged from 10% to 50%. Contraindications to conventional systemic therapies were reported by 9-22% of patients. A substantial number of patients (42%) were not satisfied with these therapies. This survey highlights the unmet need for safe and effective therapies for moderate to severe psoriasis.
The Journal of pharmacy technology, 2010
The aim of the study was conducted to find out the prevalence, types and prescribing pattern of psoria is n patients attending a tertiary care hospital. This was a non experimental prospective, cross sectional study con ducted over a period of five months. Among 6340 patients who visi ted the dermatology department of Amrita Institute of Medical Sciences, Kochi 100 patients were diagnosed to have psoriasis. The prevalence of psoriasis was found t o be 1.58%. Majority of the patients (23%) belonged to the age group of 31-40 years. The mean age of the patients was 44.17±15 and the mean age of onset of the disease w 38.34±16.05 years whereas the male-female ratio 1.3:1. Majority of the patients were diagnosed clinically and only in 26% of patients biopsy was needed to co nfirm the diagnosis. 7% of the patients were found to have a positive family history of psoriasis. Scalp was mos t common (28% of patients) initial site of onset of psoriasi s. Chronic plaque was the commonest clinical...
Epidemiological profile of patients with psoriasis
Seven Editora eBooks, 2024
Eyes on Health Sciences V.02 Epidemiological profile of patients with psoriasis CHAPTER 40 ABSTRACT Psoriasis is a disease that affects 2 to 3% of the world's population. It is a chronic, non-communicable, painful, and disabling disease for which there is no cure. Thus, this study aims to describe the epidemiological profile, quality of life, and pharmacotherapy of patients with psoriasis. For this, a descriptive and quantitative crosssectional study was conducted using online questionnaires that were applied to patients with psoriasis. The questionnaire included questions about socio-demographic data (gender, color, schooling, marital status), quality of life with questions related to day-today actions and pharmacotherapy (name of the drug, adverse reactions). We interviewed 554 individuals with a mean age of 38.72 years, with predominance of females (82.2%), white (70.1%) and with complete higher education (39.4%). The main clinical manifestations reported were scaling, itching and redness in the lesion regions. An average of 14.88 were obtained to evaluate the quality of life by the dermatology life qualify methodology. This disease causes negative impacts on patients' quality of life, mainly due to the development of other comorbidities (anxiety and depression); With this study, we confirm how psoriasis affects the quality of life of patients, since stigmatization of the individual in social environments and the adverse effects caused by drugs, in addition to promoting the appearance of other comorbidities.
Systemic management of psoriasis patients in Indian scenario: An expert consensus
Indian Dermatology Online Journal, 2021
Background: Psoriasis is a common inflammatory disease with significant comorbidities, and regardless of its extent, it affects the patients' quality of life. The various modalities of treating psoriasis comprise topical or systemic medications, phototherapy, and an array of biologic agents. There is a lack of Indian recommendations on the management of psoriasis with these different modalities and challenges faced by the clinicians in day-today practice. Aim: To develop India-specific consensus for systemic management of patients with moderate-to-severe psoriasis. Method and Results: A panel of dermatology experts, based on the evidence and international recommendations, coupled with their own clinical experience, developed recommendations for systemic management of patients with moderate-to-severe psoriasis. Conclusion: These recommendations are meant to provide guidance in terms of choice of systemic therapies, dosing, effectiveness, and safety. It also addresses clinical challenges that may be experienced during psoriasis management.
Incidence and Characteristic of Psoriasis Patients at Sanjiwani Gianyar Regional Hospital 2018-2019
Majalah Kesehatan Indonesia, 2021
Psoriasis is a chronic inflammatory skin disease that is characterized by firmly demarcated red plaque covered by a thick squama as a result of impaired proliferation and differentiation of the epidermis. Diagnosis of psoriasis is based on history taking and clinical features. Treatment is determined based on the patient's clinical characteristics and the severity of the disease. this retrospective study aims to determine the incidence, characteristics and treatment options of psoriasis patients in the dermatovenereology polyclinic of Sanjiwani Gianyar Regional Hospital in 2018-2019. Retrospective study of psoriasis patients at Sanjiwani Gianyar Regional Hospital in 2018-2019. Data collected from medical records includes sociodemographic data, clinical data and patient treatment history. Within two years, there were 53 new cases of psoriasis. The dominance of psoriasis cases was found in men with a ratio of women and men 1:2,31. From total 53 patients, 37 were male (69,81%)and 1...
Psoriasis treatment patterns: Results of a cross-sectional survey of dermatologists
Journal of the American Academy of Dermatology, 2008
The study evaluated community physician prescribing patterns for patients with psoriasis. Methods: US dermatologists actively practicing general dermatology and treating 10 or more patients with psoriasis/mo were interviewed (n = 90) in April and June 2006 and they recruited 8 to 10 consecutive patients for record review (n = 895, mean age = 46 years, 51% men). Proportion of patients treated with systemic, biologic, or topical therapy as reported by the dermatologist and recorded in the records was assessed by psoriasis severity. Results: Among patients with severe psoriasis (body surface area affected [ 10%), 56% to 63% received systemic therapy (including biologics) or phototherapy and 37% to 44% received topical therapy only. Dermatologists reported prescribing biologics to 41% of patients with severe disease compared with patient records where 27% to 34% of body surface area = 11% to 40% and 36% of body surface area greater than 40% patients received biologics. Limitations: Because of the small sample, eligibility criteria, and voluntary interview, selection bias may have occurred. Conclusions: Some dermatologists are prescribing systemic therapy for the majority of their patients with severe psoriasis but a gap in treatment remains for about 40% who received topical therapy alone.
Comorbidities associated with psoriasis: An experience from the Middle East
Journal of Dermatology, 2010
Recent studies suggest that psoriasis patients have higher rates of comorbidities. We sought to determine the prevalence of comorbidities and co-medications in our psoriasis patients. We conducted case-control study in 1835 patients with psoriasis vulgaris and age- and gender-matched cohort without psoriasis. Patients were examined for clinical characteristics of psoriasis, PASI scores, and data of age, sex, body mass index (BMI), smoking status, comorbidities, and co-medications were analysed for both patients and controls. We identified 1661 (92.8%) patients with mild to moderate psoriasis (PASI < 10) and 129 patient’s (7.03%) with severe psoriasis (PASI > 10). Patients with psoriasis were more likely to be current smokers (51.34% vs 32.51% controls). Respective prevalence rates of risk factors in those with mild–moderate psoriasis, severe psoriasis, and controls were as follows: inflammatory arthritis (20%, 31% and 10.68%); coronary heart disease (4.1%, 8.35% and 1.42%); obesity (BM1) (32.5%, 41% and 17%); diabetes mellitus type II (37.4%, 41% and 16%); hypertension (32%, 40.3% and 11.55%); dyslipidemia (14.1%, 22.48% and 4.96%); metabolic syndrome (16%, 26.35% and 6.76%); chronic obstructive pulmonary disease (COPD) (5.36%, 6.98% and 4.03%); cancer (0.3%, 1.55% and 0.16%). They had a higher odds of inflammatory arthritis, coronary heart disease, obesity, diabetes mellitus II, hypertension, dyslipidemia, and metabolic syndrome. They were receiving significantly wider varieties of drugs. Which most commonly included antidiabetic drugs, antihypertensives, and hypolipidemic drugs.